Creative Diagnostics launches specialized Rabbit Papilloma Model services for scientists.
— As an expert in providing solutions to assist virology and microbiology research, Creative Diagnostics is proud to announce the expansion of its infectious disease portfolio with the launch of its specialized Rabbit Papilloma Model services. This model provides a robust and reliable platform for scientists studying Human Papillomavirus (HPV) pathogenesis and developing next-generation vaccines and therapeutics.
Papillomaviruses (PVs) are a class of small, non-enveloped, icosahedral DNA viruses that can infect a wide range of species, including fish, reptiles, birds, and mammals. Human papillomaviruses (HPVs) are closely associated with multiple cancers in humans, particularly cervical and head and neck cancers. Therefore, there is an urgent need to establish animal models that accurately mimic human PV infection.
Most species within the Papovaviridae family are species-specific, with many strains exhibiting high specificity toward their host. Recently, the cottontail rabbit papillomavirus (CRPV) model was shown to be the most versatile preclinical model for testing antiviral agents, immune enhancers, and immunotherapeutic strategies against papillomavirus infection. Creative Diagnostics now offers a CRPV genome-mediated papilloma model on the dorsal skin of New Zealand White rabbits to facilitate HPV mechanism research and the development of novel therapeutic approaches.
Cottontail rabbit papillomavirus (CRPV), also known as Sylvilagus floridanus papillomavirus 1 (SfPV1), comprises a 7,868-bp double-stranded DNA molecule. CRPV exhibits several characteristics when used to establish papillomavirus models, including 1) Cutaneous tropism: This virus induces skin papillomas with a particular predilection for the head and neck region. Its carcinogenic potential is notably high, as these skin papillomas can spontaneously progress to squamous cell carcinoma. 2) Most studies use domestic rabbits, particularly New Zealand White rabbits, for experimental infection. 3) Viral gene construction for modeling uses isolated CRPV viral DNA obtained by cloning the complete CRPV genome into a vector.
Creative Diagnostics has successfully developed a papilloma model by inducing skin lesions through deep scratches on the back of male New Zealand white rabbits, followed by inoculation with the CRPV genomic plasmid. In this model, distinct papillomatous lesions become observable at the inoculation site on the rabbit’s back approximately five weeks after viral DNA challenge.
This model is suitable for investigating viral pathogenic mechanisms, gene function, and virus-host interactions. It can also be used for testing HPV-related vaccines and developing and validating antiviral and anti-tumor compounds. Creative Diagnostics offers these services to support HPV virology and therapeutic testing research and development.
“The complexity of the papillomavirus life cycle makes in vitro cultivation a significant hurdle for researchers,” said the Program Manager at Creative Diagnostics. “By utilizing the CRPV in New Zealand White rabbits, this model provides a critical bridge in preclinical HPV research, and offers a highly translatable system for studying viral pathogenesis and oncogenic progression.”
For more information on these models or related innovative solutions for preclinical research involving infectious diseases, please visit https://antiviral.creative-diagnostics.com/rabbit-papilloma-model-for-hpv-related-research.html.
About Creative Diagnostics
Headquartered in New York, Creative Diagnostics is a consulting and experimental service provider specializing in virology and microbiology. The company provides comprehensive solutions to conquer obstacles in virology and microbiology research, from high-security infrastructure provision, biosafety regulation elucidation, to expert viral system assistance.
Contact Info:
Name: Thomas Schmitt
Email: Send Email
Organization: Creative Diagnostics
Website: https://antiviral.creative-diagnostics.com/
Release ID: 89181799
If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). We will respond and rectify the situation in the next 8 hours.